Rituximab, bendamustine look better than chemo alone in MCLSeptember 7, 2019Lymphoma & Plasma Cell Disorders
Progressive myeloma after induction? Go straight to transplantSeptember 6, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Ibrutinib-rituximab induction yields ‘unprecedented’ responses in MCLAugust 27, 2019Lymphoma & Plasma Cell DisordersHematology
Review of Radiologic Considerations in an Immunocompetent Patient With Primary Central Nervous System Lymphoma (FULL)August 7, 2019Lymphoma & Plasma Cell DisordersOncology
BRCA2 mutations linked to childhood NHLJuly 25, 2019HematologyOncologyLymphoma & Plasma Cell Disorders
Lymphoma risk prompts FDA recall of Allergan’s textured breast implantsJuly 24, 2019Lymphoma & Plasma Cell DisordersOncology
SC daratumumab deemed feasible for every multiple myeloma patientJuly 11, 2019Multiple MyelomaLymphoma & Plasma Cell DisordersHematology
CNS-directed therapy appears more effective for synDLBCLJuly 9, 2019Lymphoma & Plasma Cell DisordersHematology
Cell count ratios appear to predict thromboembolism in lymphomaJune 25, 2019Lymphoma & Plasma Cell DisordersHematology
Partners in Oncology Care: Coordinated Follicular Lymphoma Management (FULL)June 25, 2019Lymphoma & Plasma Cell DisordersOncology
Chemo-free Smart Start regimen looks promising in poor-prognosis DLBCLJune 7, 2019Lymphoma & Plasma Cell Disorders
Daratumumab regimen shows benefit in transplant-ineligible myelomaMay 29, 2019Multiple MyelomaLymphoma & Plasma Cell DisordersHematology
Lenalidomide may reduce risk of progression from SMM to MMMay 16, 2019Multiple MyelomaLymphoma & Plasma Cell DisordersHematology
